Is Ketamine the Future of Mental Health Treatment?

What the Coverage Is Saying

A recent segment from Baltimore's WBAL-TV declared that ketamine therapy "could be the future of mental health treatment" — and while that framing is bold, it reflects a genuine shift in how mainstream media and the broader medical community are beginning to talk about a drug that, not long ago, was known mainly as an anesthetic and a party drug.

Stories like this one are appearing with growing frequency in local news markets across the country. That pattern matters: it signals that ketamine is moving from fringe conversation to something family physicians, insurers, and patients are starting to take seriously. Understanding what's driving that momentum — and where the limits are — helps patients make better decisions.

Why Ketamine Is Generating This Kind of Attention

The clinical case for ketamine in mental health is not new, but it has grown substantially more solid over the past decade. The FDA approved esketamine (Spravato), a nasal spray derived from ketamine, in 2019 for treatment-resistant depression and for major depressive disorder with acute suicidal ideation. That approval gave providers a legal, insurance-reimbursable path to ketamine-adjacent treatment — and it opened broader conversations about IV ketamine infusions and other off-label protocols.

What drives the excitement is speed. Traditional antidepressants can take weeks to produce noticeable effects, if they work at all. Ketamine, by contrast, can produce rapid relief — sometimes within hours — in patients who have failed multiple prior treatments. For someone who has cycled through several medications without improvement, that difference isn't a minor detail. It can be life-changing, and in cases of acute suicidality, potentially lifesaving.

Research continues to strengthen the evidence base for ketamine in treatment-resistant depression, bipolar depression, PTSD, and OCD, though the evidence is stronger for some of these conditions than others. The field is still working out optimal dosing, session frequency, and long-term maintenance protocols — areas where clinical practice has run ahead of the published literature.

What Patients Comparing Options Should Understand

Not all ketamine delivery is the same. The two routes patients most commonly encounter are IV infusion (administered in a clinical setting over roughly 40–60 minutes) and intranasal esketamine (Spravato, self-administered under in-office supervision). Oral ketamine lozenges and intramuscular injections also appear in some clinical protocols. Each route carries different bioavailability, duration of effect, cost, and monitoring requirements. IV infusions are prescribed off-label for psychiatric use but have the longest clinical track record in this space.

Cost and access remain real barriers. Spravato can qualify for insurance coverage under specific diagnostic criteria, but IV ketamine infusions are typically out-of-pocket, with a full initial course of treatment often running $2,000–$4,000 or more depending on location and clinic. That gap puts ketamine out of reach for many patients who might benefit most — particularly those with chronic, severe depression who have already exhausted lower-cost options.

Provider quality varies significantly. As ketamine clinics have proliferated, so has variation in clinical protocols, screening rigor, and integration support. Patients should look for providers who conduct thorough psychiatric evaluations, screen for contraindications like uncontrolled hypertension or active psychosis, and provide clear guidance on what to expect during and after each session.

The Bigger Picture

The surge in local news coverage reflects something larger than a trend: ketamine therapy is entering the mainstream conversation precisely because the mental health system is under enormous strain. Rates of treatment-resistant depression, PTSD, and anxiety disorders remain high, and the pipeline for genuinely novel psychiatric drugs has historically been thin. Ketamine — and its chemical relatives, including emerging psychedelic-assisted therapies — represents one of the few categories where the underlying mechanism is meaningfully different from the monoamine-targeting approaches that have dominated psychiatry for decades.

Whether that makes ketamine "the future" depends on which problems get solved next. Greater insurance coverage, standardized clinical protocols, more robust long-term outcome data, and expanded access in underserved communities would each move the needle substantially. For now, it occupies a valuable but still-limited niche: a fast-acting, evidence-backed option for people who haven't found relief through conventional treatment.

Read the original WBAL-TV segment here.